Company intelligence / Profile preview

Perpetual Discovery

Shanghai, Shanghai, Chinaourperpetualdiscovery.wordpress.com ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Perpetual Medicines has developed an AI-driven computational peptide drug discovery engine. As of early 2024, it has three major preclinical oncology programs targeting intracellular PPIs—an area where peptides offer unique advantages over small molecules or antibodies. The company also has preclinical efforts in autoimmunity and metabolic disease. No clinical results have been reported yet; the most advanced program is expected to enter clinical trials soon.

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: PeptidesRecombinant peptideBiologic
Industry: Biotech

Beyond the preview

Go deeper on Perpetual Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perpetual Discovery.

Explore the full profile